Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of EA3571 in healthy adult subjects
jRCT2051220036Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing EA3571 with Placebo (2 arms). Primary endpoints: Safety endpoints and Pharmacokinetics endpoints. Started Jun 2022; status: completed.
02
Drugs
EA-3571
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2051220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220036.